On November 13, 2026 Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics ("Molecular Partners" or the "Company"), reported it will present the Company’s latest developments and outlook at the Inaugural UBS Biopharma Conference, taking place 16–17 November 2026 in London, United Kingdom.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chief Executive Officer Patrick Amstutz will present on Tuesday, November 17 at 8am GMT (9am CET) at the Rosewood Hotel in London.

A webcast will be accessible on the Molecular Partners website, under the Events tab.

(Press release, Molecular Partners, NOV 13, 2026, View Source [SID1234674775])